IBD

R&D

The rise and market race of anti-IL23p19 therapies in IBD: H...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades.

R&D

Into the bowels of gut research

For people living with Inflammatory Bowel Disease (IBD), navigating life around the risk of flare-ups can be a messy and exhausting challenge.

R&D

Highlights & Headlines from Deep Dive: R&D

pharmaphorum’s Deep Dive magazine is back to explore trends, challenges, & innovations in R&D.

News

Sanofi, CytoReason expand AI deal into IBD

Tech company CytoReason has announced it has signed a multi-year, multimillion dollar deal with Sanofi to deliver artificial intelligence (AI) for drug discovery and development in the fiel

Digital

How digital pathways are changing healthcare

As demonstrated throughout COVID, digital health is no longer experimental.

Events

Partner Content

PREDiCT: Autoimmune Disease Modeling Summit

Deploy Advanced Models to Enhance Your Confidence & Und

The rise and market race of anti-IL23p19 therapies in IBD: H...

Into the bowels of gut research

Highlights & Headlines from Deep Dive: R&D

Sanofi, CytoReason expand AI deal into IBD

How digital pathways are changing healthcare

PREDiCT: Autoimmune Disease Modeling Summit

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

IBD

Editor's Picks